Antipsychotic Effects on Brain Function in Schizophrenia

• Status: Terminated
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether two commonly-prescribed antipsychotic medications (aripiprazole and risperidone) have different effects on brain function and cognition in schizophrenia patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: The Dana Foundation
• Treatments: Antipsychotic Agents; Aripiprazole; Armodafinil; Modafinil; Risperidone

Criteria

Inclusion Criteria:

• less than 40 years old;

• currently meet criteria for schizophrenia, schizophreniform disorder or schizoaffective disorder from the DSM-IV-TR;

• require new or changed treatment with antipsychotic medication.

Exclusion Criteria:

• older than 40 years;

• in current antipsychotic treatment that is satisfactory;

• treatment-refractory psychosis;

• active substance-related disorder;

• clinically-unstable (e.g. acute symptoms requiring emergent or acute-care, including acute suicide risk);

• neurological illness or poorly-controlled medical illness;

• currently taking medications for serious medical illness which have significant interactions with modafinil;

• active pregnancy;

• intelligence less than 70 (on standard test);

• contraindications for fMRI (e.g. claustrophobia, metal foreign bodies, etc.);

• uncorrectable visual acuity impairment.